Ann: EMORY JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL, page-8

“With the successful launch of our fourth and final clinical trial site in the USA; we’ve reached a
significant milestone in our development program. This momentum reflects our unwavering
commitment to advancing cell therapy and positions us to deliver meaningful value to both
patients and shareholders,” said Dr Rebecca McQualter, Chimeric Therapeutics’ Chief Executive
Officer.

I agree, that should speed up the trials a bit as the initial preparations are always a bit tricky. But once set up it should go a bit faster.

Let's hope for sufferers and you holders.